Following the COVID-19 pandemic, increases were seen in the global disease burden of malaria, depressive disorders, and anxiety disorders.

The design of recruitment tools for clinical trials impacts rates of enrollment, with higher enrollment seen for shorter letters.

Patients with AD treated with dupilumab have a lower risk of various infections than those treated with methotrexate or cyclosporine.